SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cerecor Inc. on January 10, 2016. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Appointment: On January 10, 2016, the Board appointed Thomas H. Aasen as a Class III director.
- Committee Assignment: Mr. Aasen was appointed as a member of the Audit Committee.
- Background: Mr. Aasen brings extensive financial management experience from the biopharmaceutical sector, having previously served as Executive Vice President, CFO, and Chief Business Officer at Acadia Pharmaceuticals Inc. (1998–2014). He also held roles at Axys Pharmaceuticals, Genta, Inc., Gen-Probe, Inc., and KPMG Peat Marwick.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks. The Board stated that Mr. Aasen's experience will make him a valuable member. The report includes a Regulation FD disclosure noting a press release issued on January 12, 2016, regarding the appointment.
Key Facts for Investor Verification
- Verify the effective date of Thomas Aasen's appointment (January 10, 2016).
- Confirm Mr. Aasen's specific role on the Audit Committee.
- Review the attached press release (Exhibit 99.1) for additional details on the appointment.
- Note that this filing does not impact the company's financial statements or operational metrics.